ENXTAM:PHARMBiotechs
Assessing Pharming Group (ENXTAM:PHARM) Valuation After 2026 Revenue Guidance For Joenja And RUCONEST
2026 revenue guidance puts Joenja and RUCONEST in focus
Pharming Group (ENXTAM:PHARM) has issued earnings guidance for 2026, projecting total revenues between US$405 million and US$425 million. This outlook is framed around growth in Joenja and continued contributions from RUCONEST.
See our latest analysis for Pharming Group.
The 2026 revenue guidance comes after a mixed few months for the stock, with a 16.71% 1 month share price return decline and a 9.02% year to date share price return...